JTK 303

an HIV-1 integrase inhibitor; structure in first source
Also Known As:
GS 9137; GS-9137; GS9137; JTK-303; JTK303; elvitegravir
Networked: 40 relevant articles (5 outcomes, 6 trials/studies)

Relationship Network

Bio-Agent Context: Research Results


1. DeJesus, Edwin: 7 articles (06/2015 - 03/2011)
2. Szwarcberg, Javier: 7 articles (03/2014 - 06/2012)
3. Cheng, Andrew K: 6 articles (06/2015 - 06/2012)
4. Liu, Hui C: 5 articles (08/2015 - 03/2011)
5. Gathe, Joseph: 5 articles (08/2015 - 06/2012)
6. De Clercq, Erik: 5 articles (11/2013 - 01/2008)
7. Mills, Anthony: 4 articles (08/2015 - 06/2012)
8. Plummer, Andrew: 4 articles (06/2015 - 04/2013)
9. Sax, Paul E: 4 articles (06/2015 - 06/2012)
10. White, Kirsten: 4 articles (07/2014 - 06/2012)

Related Diseases

1. Infection
2. Proteinuria
3. HIV Infections (HIV Infection)
4. Human Influenza (Influenza)
11/15/2013 - "In this second part of "Dancing with antivirals as chemical formulae" I will focus on a number of chemical compounds that in the last few years have elicited more than common attraction from a commercial viewpoint: (i) favipiravir (T-705), as it is active against influenza, but also several other RNA viruses; (ii) neuraminidase inhibitors such as zanamivir and oseltamivir; (iii) peramivir and laninamivir octanoate, which might be effective against influenza virus following a single (intravenous or inhalation) administration; (iv) sofosbuvir, the (anticipated) cornerstone for the interferon-free therapy of HCV infections; (v) combinations of DAAs (direct antiviral agents) to achieve, in no time, a sustained virus response (SVR) against HCV infection; (vi) HIV protease inhibitors, the latest and most promising being darunavir; (vii) the integrase inhibitors (INIs) (raltegravir, elvitegravir, dolutegravir), representing a new dimension in the anti-HIV armamentarium; (viii), a new class of helicase primase inhibitors (HPIs) that may exceed acyclovir and the other anti-herpes compounds in both potency and safety; (ix) CMX-001, as the latest of Dr. Antonín Holý's legacy for its activity against poxviruses and CMV infections, and (x) noroviruses for which the ideal antiviral compounds are still awaited for. "
09/01/2008 - "Foremost among the newly described antiviral agents that may be developed into drugs are, for the treatment of human papilloma virus (HPV) infections, cPrPMEDAP; for the treatment of herpes simplex virus (HSV) infections, BAY 57-1293; for the treatment of varicella-zoster virus (VZV) infections, FV-100 (prodrug of Cf 1743); for the treatment of cytomegalovirus (CMV) infections, maribavir; for the treatment of poxvirus infections, ST-246; for the treatment of hepatitis B virus (HBV) infections, tenofovir disoproxil fumarate (TDF) (which in the meantime has already been approved in the EU); for the treatment of various DNA virus infections, the hexadecyloxypropyl (HDP) and octadecyloxyethyl (ODE) prodrugs of cidofovir; for the treatment of orthomyxovirus infections (i.e., influenza), peramivir; for the treatment of hepacivirus infections (i.e., hepatitis C), the protease inhibitors telaprevir and boceprevir, the nucleoside RNA replicase inhibitors (NRRIs) PSI-6130 and R1479, and various non-nucleoside RNA replicase inhibitors (NNRRIs); for the treatment of human immunodeficiency virus (HIV) infections, integrase inhibitors (INIs) such as elvitegravir, nucleoside reverse transcriptase inhibitors (NRTIs) such as apricitabine, non-nucleoside reverse transcriptase inhibitors (NNRTIs) such as rilpivirine and dapivirine; and for the treatment of both HCV and HIV infections, cyclosporin A derivatives such as the non-immunosuppressive Debio-025."
5. Fatigue

Related Drugs and Biologics

1. emtricitabine (Emtriva)
2. tenofovir
3. MK 0518
4. tenofovir disoproxil (Viread)
5. Ritonavir (Norvir)
6. Integrase Inhibitors
7. Protease Inhibitors (Protease Inhibitor)
8. Antiviral Agents (Antivirals)
9. darunavir (Prezista)
10. peramivir

Related Therapies and Procedures

1. Inhalation Administration